Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435959 | 0.98 | MEN1 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30374046 | 0.98 | ALOX15 (0.46) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL7283602 | 0.98 | MEN1 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL5497459 | 0.98 | MEN1 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL1774553 | 0.98 | MEN1 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL261594 | 0.93 | — | — | |
| SCHEMBL17384745 | 0.84 | ALOX15 (0.48) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL4318601 | 0.84 | — | — | |
| SCHEMBL28356938 | 0.83 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL7380515 | 0.83 | ALOX15 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305198-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURG (GB) | 2010-12-02 | — | — | US | claimed |
| EP-2212279-A1 | CATIONIC LIPIDS | The University Court Of The University of Edinburgh (GB) | 2010-08-04 | — | — | EP | claimed |
| WO-2009050483-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2009-04-23 | — | — | WO | claimed |
| EP-0334244-A2 | Bradykinin Antagonist Peptides | THE PROCTER & GAMBLE COMPANY (US) | 1989-09-27 | — | — | EP | claimed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| US-11779602-B2 | Methods of use for CAR T cells | ENDOCYTE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779602-B2 | Methods of use for CAR T cells | ENDOCYTE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | ENDOCYTE, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | ENDOCYTE, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | ENDOCYTE INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-11311576-B2 | Methods of use for CAR T cells | SEATTLE CHILDREN'S HOSPITAL (US) | 2022-04-26 | — | — | US | disclosed |
| EP-0464517-A2 | Amino acid derivatives with renin inhibiting activity | MERCK PATENT GmbH (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| EP-0334244-A2 | Bradykinin Antagonist Peptides | THE PROCTER & GAMBLE COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311576-B2 | Methods of use for CAR T cells | CD47, CD4, CD2 | ALOX15 2145/4885MEN1 3960/4885CYP1A2 4676/4885 |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | ALOX15 4479/4885MEN1 691/4885CYP1A2 4702/4885 |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | CD47, PBK, GZMB | ALOX15 2537/4885MEN1 2451/4885CYP1A2 4876/4885 |
| US-11779602-B2 | Methods of use for CAR T cells | CD47, CD4, CD2 | ALOX15 2145/4885MEN1 3960/4885CYP1A2 4676/4885 |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | ALOX15 821/4885MEN1 1102/4885CYP1A2 2973/4885 |
| US-20100305198-A1 | CATIONIC LIPIDS | CETP, LIPA, ABHD16A | ALOX15 892/4885MEN1 1595/4885CYP1A2 4828/4885 |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | ALOX15 969/4885MEN1 4772/4885CYP1A2 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.